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Test group Parameter Admission (October 2016)
Follow up 
(February 2017) Reference intervals
CBC
WBC (x109/L) 1.3 1.33 4-11
Neutrophils (x109/L) 0.1 0.48 2.5-7.5
Lymphocytes (x109/L) 0.52 0.31 1-4.5
Monocytes (x109/L) 0.59 0.43 0.2–1.0
Haemoglobin (g/L) 143 166 130-175
Platelets (x109/L) 54 93 130-400
Chemistry
AST (U/L) 47 44 0-38
LD (U/L) 308 251 135-225
β-2 MG (µg/mL) 3.7 3.9 0.8-2.2
CRP (mg/L) 44 - 0-5
Immunology
IgG (g/L) 7.64 10.60 7.00–16.00
IgA (g/L) 0.90 1.37 0.7–4.0
IgM (g/L) 3.62 4.03 0.4-2.3
Serology
HBSAG Negative - Negative
HBCAC Negative - Negative
HCAC Negative - Negative
HIVAC Negative - Negative
EBIGM Negative - Negative
EBIGG Positive - Negative
CMVIGM Negative - Negative
CMVIGG Positive - Negative
MUMPSIGG Negative - Negative
MUMPSIGM Negative - Negative
Autoimmunity
Anti-neutrophil antibodies Positive* - Negative
Anti-platelet antibodies Positive† - Negative
*Presence of IgG and IgM anti-neutrophil antibodies attached to cell surface (direct test) and free in serum (indirect test).
†IgG anti-platelet antibodies (cut-off > 30%). CBC - complete blood count. WBC - white blood cell count. AST – aspartate-amino-
transferase. LD – lactate-dehydrogenase. B-2 MG - beta-2 microglobulin. CRP - C - reactive protein. Ig – immunoglobulin. CMV – 
cytomegalovirus. HIV - human immunodeficiency virus. EB - Epstein-Barr virus. HBSAG - hepatitis B surface antigen index (cut-off 
< 1). HBCAC - anti-hepatitis B core antigen index (cut-off > 1). HCAC - hepatitis C antibody index (cut-off < 1). HIVAC - human 
immunodeficiency virus antibody + p24 antigen index (cut-off < 1). EBIGM - IgM antibodies to Epstein-Barr viral capsid antigens 
(cut-off < 20 U/mL). EBIGG - IgG antibodies to Epstein-Barr viral capsid antigens (cut-off < 20 U/mL). CMVIGM - IgM antibodies to 
human cytomegalovirus (cut-off < 18 U/mL). CMVIGG - IgG antibodies to human cytomegalovirus (cut-off < 12 U/mL). MUMPSIGM 
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